Le Lézard
Classified in: Health, Science and technology, Business
Subjects: PDT, LIC

Agena Bioscience Bolsters MassARRAY Insightstm Reporting Network By Adding N-of-One



SAN DIEGO, Oct. 5, 2017 /PRNewswire/ -- Agena Bioscience, a global provider of molecular genetic solutions and N-of-One Inc., a leader in molecular decision support for oncology, have teamed together to provide interpretation of cancer genomic data generated by the MassARRAY® System.

Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAYÂ(R) System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. (PRNewsFoto/Agena Bioscience) (PRNewsFoto/)

This strategic partnership supports the expansion of Agena's recently launched MassARRAY Insights reporting network, which connects the unique capabilities of the MassARRAY with the power of high quality analysis to aid in results interpretation. N-of-One's long standing expertise in clinical interpretation of molecular tests in oncology aids CLIA High Complexity Labs in rapidly delivering actionable, patient-specific treatment options that are supported by the latest scientific and clinical evidence.

"MassARRAY Insights is part of Agena Bioscience's continued effort to support our CLIA-High Complexity Certified lab customers who are tackling the challenges presented in molecular diagnostics. We are happy to partner with an industry leader like N-of-One to help bring our lab clients an important component that nicely follows the value of our test: an evidence-based, clinically actionable report," said Pete Dansky, Chief Executive Officer at Agena Bioscience.

"With technology like Agena's MassARRAY, clinicians have the ability to develop tests that provide robust data. With our data interpretation expertise, we can guide pathologists and oncologists to more precise and tailored cancer treatments than ever before. At N-of-One, we are happy to partner with Agena Bioscience, as we are aligned in tackling complex molecular data and helping to make sense of it for the clinician," said Chris Cournoyer, Chief Executive Officer at N-of-One, Inc."

Agena's MassARRAY System is intended for Research Use Only. Not for use in diagnostic procedures.

MassARRAY Insights reporting networks can be found at www.agenabio.com/services/insights

About Agena Bioscience

Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. For more information about Agena, visit www.agenabio.com.

About N-of-One
N-of-One is a leader in identifying patient-specific therapeutic options for precision medicine in oncology by leveraging its proprietary knowledgebase and its team of oncologists and Ph.D. scientists to integrate molecular data from multiple tests. Using N-of-One solutions can standardize and accelerate genomic clinical interpretation and molecular decision support while saving time and money. N-of-One's solutions have provided therapeutic options, including clinical trials, for tens of thousands of patient cases across hundreds of cancer types. N-of-One partners with leading hospital systems, cancer centers, and commercial labs around the world. For more information, please visit www.n-of-one.com or call +1 617-202-9808.

 

SOURCE Agena Bioscience


These press releases may also interest you

at 21:00
iFlytek, the largest publicly-listed AI technology company in the Asia-Pacific region has further advanced its healthcare initiative by leading the Pre-A round investment into Cyrcadia Asia, a company developing a smart wearable bra insert that...

at 13:51
Massage Envy Franchising, LLC today noted factual inaccuracies in recently publicized communications regarding campaign contributions to Secretary of State and Gubernatorial candidate, Brian Kemp. "Because our company was mentioned in the letter, we...

at 13:00
MEMPHIS, Tenn., July 15, 2018 /PRNewswire-PRWeb/ -- Achieving The National Committee for Quality Assurance (NCQA) status has been a recognized achievement for West Clinic also known as the West Cancer Center since 2012. We are honored to be 1 of 36...

at 09:00
Next time you step outside to enjoy the summer sun, don't forget to bring a pair of sunglasses. Most people know that the sun's damaging ultraviolet rays are bad for the skin. But did you know that too much sun on unprotected eyes increases the risk...

at 00:00
TARPON SPRINGS, Fla., July 15, 2018 /PRNewswire-PRWeb/ -- Florida Hospital North Pinellas has received the American Heart Association/American Stroke Association's Get With The Guidelines®-Stroke Gold Plus Quality Achievement Award. The award...

14 jui 2018
NEWPORT BEACH, Calif., July 14, 2018 /PRNewswire-PRWeb/ -- A July 1 article in the Orange County Register reports on the ongoing popularity of all types of plastic surgery and cosmetic procedures, offering some detailed advice on the importance of...




News published on 5 october 2017 at 09:17 and distributed by: